Literature DB >> 17488727

Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3.

Annette Haacke1, F Ulrich Hartl, Peter Breuer.   

Abstract

The formation of intraneuronal inclusions is a common feature of neurodegenerative polyglutamine disorders, including Spinocerebellar ataxia type 3. The mechanism that triggers inclusion formation in these typically late onset diseases has remained elusive. However, there is increasing evidence that proteolytic fragments containing the expanded polyglutamine segment are critically required to initiate the aggregation process. We analyzed ataxin-3 proteolysis in neuroblastoma cells and in vitro and show that calcium-dependent calpain proteases generate aggregation-competent ataxin-3 fragments. Co-expression of the highly specific cellular calpain inhibitor calpastatin abrogated fragmentation and the formation of inclusions in cells expressing pathological ataxin-3. These findings suggest a critical role of calpains in the pathogenesis of Spinocerebellar ataxia type 3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488727     DOI: 10.1074/jbc.M611914200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

2.  Nuclear aggregation of polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic quality control.

Authors:  Peter Breuer; Annette Haacke; Bernd O Evert; Ullrich Wüllner
Journal:  J Biol Chem       Date:  2010-01-11       Impact factor: 5.157

3.  Therapeutic prospects for spinocerebellar ataxia type 2 and 3.

Authors:  Ilya Bezprozvanny; Thomas Klockgether
Journal:  Drugs Future       Date:  2009-12       Impact factor: 0.148

Review 4.  Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer's disease.

Authors:  Polina Egorova; Elena Popugaeva; Ilya Bezprozvanny
Journal:  Semin Cell Dev Biol       Date:  2015-04-04       Impact factor: 7.727

5.  Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.

Authors:  Philipp Koch; Peter Breuer; Michael Peitz; Johannes Jungverdorben; Jaideep Kesavan; Daniel Poppe; Jonas Doerr; Julia Ladewig; Jerome Mertens; Thomas Tüting; Per Hoffmann; Thomas Klockgether; Bernd O Evert; Ullrich Wüllner; Oliver Brüstle
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

6.  Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.

Authors:  Maria do Carmo Costa; Naila S Ashraf; Svetlana Fischer; Yemen Yang; Emily Schapka; Gnanada Joshi; Thomas J McQuade; Rahil M Dharia; Mark Dulchavsky; Michelle Ouyang; David Cook; Duxin Sun; Martha J Larsen; Jason E Gestwicki; Sokol V Todi; Magdalena I Ivanova; Henry L Paulson
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

7.  Cathepsins L and Z are critical in degrading polyglutamine-containing proteins within lysosomes.

Authors:  Nidhi Bhutani; Rosanna Piccirillo; Raphael Hourez; Prasanna Venkatraman; Alfred L Goldberg
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

8.  Calcium signaling and neurodegenerative diseases.

Authors:  Ilya Bezprozvanny
Journal:  Trends Mol Med       Date:  2009-02-21       Impact factor: 11.951

Review 9.  Nuclear accumulation of polyglutamine disease proteins and neuropathology.

Authors:  Lauren S Havel; Shihua Li; Xiao-Jiang Li
Journal:  Mol Brain       Date:  2009-07-03       Impact factor: 4.041

10.  Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3.

Authors:  Joonil Jung; Kexiang Xu; Derek Lessing; Nancy M Bonini
Journal:  Hum Mol Genet       Date:  2009-09-25       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.